Executive Interviews

81. What To Expect From Cell Therapy And Gene Therapy In 2022 And Beyond 12/1/2021

    From innovations in clinical development and manufacturing to the evaluation of investigational cell and gene therapies (CGTs), subject matter experts from Cellectis and Immatics share a brief look back on 2021 and a detailed glimpse into the near future of gene therapy and cell therapy respectively.

82. Long Hauler In The Antibiotics Space 11/1/2021

    For Ted Schroeder, CEO of Nabriva Therapeutics, the road of his biopharma career led him into the antibiotics space, a mighty steep climb in the biopharma industry.

83. Jaguar Health's Lisa Conte — An Entrepreneurial Ascent Like No Other 11/1/2021

    Lisa Conte’s idea was to do more efficient drug discovery and development by leveraging the knowledge of “traditional healers.” However, like most entrepreneurial climbs, it would prove arduous, with plenty of slips, trips, and spills along the way.

84. Going Precommercial — From The Commercial World 10/1/2021

    Nancy Lurker, a veteran Big-Pharma marketer, now runs a small biopharma. And she admits, “the business models are very, very different.”

85. $4 Billion In 4 Years: The Story Of SpringWorks Therapeutics 10/1/2021

    Saqib Islam was one of the five founding members of SpringWorks Therapeutics, which was spun out of Pfizer in 2017. An atypical startup, the company launched with the rights to four clinical-stage experimental therapies and grew quickly in the next few years.

86. Becoming A Clinical-Stage Biotech 9/1/2021

    A Q&A with Laura Indolfi, CEO and cofounder of PanTher Therapeutics, which recently closed its Series A funding round and is preparing for its first clinical trials.

87. What's It Like Being A First-Time Biopharma CEO? 9/1/2021

    In this edited transcript of our June 2021 executive virtual roundtable, three first-time CEOs tell us their tales of the good, the bad, and the ugly related to being CEO.

88. 35-Year Biopharma R&D Vet Takes On His Second Startup 9/1/2021

    Norbert Bischofberger, Ph.D., had a good job at Gilead where he had worked for nearly two decades. Then, out of the blue, he found out he was being considered for a CEO position at a small startup called Kronos Bio.

89. Coming Out Of Stealth Mode: What To Know And Do 8/2/2021

    In Part two of this two-part series, we look at what companies should do to make the exit from stealth mode an effective exchange with the outside world — how to identify and reach investors, influencers, and stakeholders in a company’s pursuit of new treatments for diseases, from rare conditions to widespread medical challenges, some at the scale of public health.

90. A Q&A With A Biotech Founder/Entrepreneur 8/2/2021

    Since cofounding Kymera Therapeutics, Nello Mainolfi, Ph.D., has served as CSO, CTO, and now is president and CEO. He helped Kymera bring the first ever targeted protein degrader to the clinic, go public in 2020, and land significant partnerships with the likes of GSK, Vertex, and Sanofi.